The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)